Literature DB >> 18539198

Inducing an anergic state in mast cells and basophils without secretion.

Donald MacGlashan1, Bradley J Undem.   

Abstract

BACKGROUND: IgE-mediated secretion from mast cells or basophils depends on the activity of both spleen tyrosine kinase (syk) and phosphatidyl inositol 3' kinase (PI3K), but several specific downregulatory pathways (eg, loss of syk expression) do not.
OBJECTIVE: We tested whether stimulation with antigen in the presence of a syk inhibitor (NVP-QAB205) would ablate secretion while simultaneously allowing anergy.
METHODS: The anergic or desensitized state in human basophils, cultured-derived mast cells, and in situ stimulated airway mast cells (in organ baths) was assessed after stimulation with antigen in the presence of syk inhibitor.
RESULTS: Antigen caused 35 +/- 7% and 62 +/- 10% histamine release from basophils and mast cells, respectively, and it caused an 87 +/- 5% histamine/leukotriene D(4)-dependent contraction of human isolated bronchi. All of these responses were blocked >95% by the syk inhibitor. Rechallenging the preparations with antigen, after first washing out the syk inhibitor and antigen, revealed that near complete anergy (92% to 100%) occurred in each case. A similar result was found when using a PI3K inhibitor, LY294002, in studies of basophils.
CONCLUSION: Although the syk inhibitor nearly abolished the antigen-induced secretion from mast cells and basophils, it had little effect on the pathways involved in anergy. These results suggest that syk and PI3K are not involved in downregulation leading to anergy.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18539198     DOI: 10.1016/j.jaci.2008.04.019

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  16 in total

1.  Marked differences in the signaling requirements for expression of CD203c and CD11b versus CD63 expression and histamine release in human basophils.

Authors:  Donald MacGlashan
Journal:  Int Arch Allergy Immunol       Date:  2012-06-20       Impact factor: 2.749

2.  Polymerization of actin does not regulate desensitization in human basophils.

Authors:  Donald MacGlashan; Natalia Vilariño
Journal:  J Leukoc Biol       Date:  2009-01-15       Impact factor: 4.962

Review 3.  Pros and Cons of Clinical Basophil Testing (BAT).

Authors:  Hans Jürgen Hoffmann; Edward F Knol; Martha Ferrer; Lina Mayorga; Vito Sabato; Alexandra F Santos; Bernadette Eberlein; Anna Nopp; Donald MacGlashan
Journal:  Curr Allergy Asthma Rep       Date:  2016-07       Impact factor: 4.806

Review 4.  IgE-dependent signaling as a therapeutic target for allergies.

Authors:  Donald W MacGlashan
Journal:  Trends Pharmacol Sci       Date:  2012-06-30       Impact factor: 14.819

5.  Inhibition of IgE-mediated secretion from human basophils with a highly selective Bruton's tyrosine kinase, Btk, inhibitor.

Authors:  Donald MacGlashan; Lee A Honigberg; Ashley Smith; Joseph Buggy; John T Schroeder
Journal:  Int Immunopharmacol       Date:  2011-01-14       Impact factor: 4.932

6.  Subthreshold desensitization of human basophils re-capitulates the loss of Syk and FcεRI expression characterized by other methods of desensitization.

Authors:  D MacGlashan
Journal:  Clin Exp Allergy       Date:  2012-07       Impact factor: 5.018

Review 7.  Immunotherapy in food allergy.

Authors:  Toral Kamdar; Paul J Bryce
Journal:  Immunotherapy       Date:  2010-05       Impact factor: 4.196

Review 8.  The role of basophils as innate immune regulatory cells in allergy and immunotherapy.

Authors:  Salvatore Chirumbolo; Geir Bjørklund; Andrea Sboarina; Antonio Vella
Journal:  Hum Vaccin Immunother       Date:  2018-01-18       Impact factor: 3.452

Review 9.  Immunology in the Clinic Review Series; focus on allergies: basophils as biomarkers for assessing immune modulation.

Authors:  S U Patil; W G Shreffler
Journal:  Clin Exp Immunol       Date:  2012-01       Impact factor: 4.330

10.  Regulation of Syk kinase and FcRbeta expression in human basophils during treatment with omalizumab.

Authors:  Asifa K Zaidi; Sarbjit S Saini; Donald W Macglashan
Journal:  J Allergy Clin Immunol       Date:  2010-03-17       Impact factor: 10.793

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.